Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Exploring Cytoprotective Mechanisms in the Immune Evasion of Bladder Cancer

FY 2025-26

Summary
Bladder cancer is the tenth most prevalent cancer worldwide, and the number of new cases per year is expected to double by 2040. Immunotherapy has emerged as an effective way to stimulate the immune system against cancer, and while this has improved clinical outcomes, most bladder cancer patients do not respond well. In order to work toward better treatments, we must understand how bladder cancer evades immune killing. Recent studies have shown that immune attacks on tumour cells are usually sublethal; to kill tumour cells, immune cells have to inflict more damage than their target can recover from, as cancer cells use cytoprotective pathways to mitigate damage. However, the clinical relevance of these pathways in immune evasion has not been explored. We propose that cytoprotective pathways in bladder cancer cells contribute to resistance to immune killing, and we aim to identify relevant mechanisms of immune evasion in human bladder tumours. To investigate this, human T cells will be co-cultured with bladder cancer cell lines, and tumour cell survival will be assessed through either live-cell imaging or flow cytometry. These results will indicate which cell lines are more resistant to immune killing, and RNA sequencing will be used to identify possible mechanisms of resistance. To confirm their clinical relevance, these results will be compared with pathways identified in data from human bladder cancer patients. Candidate pathways will then be blocked or stimulated in co-culture assays to validate whether changing their level of function impacts sensitivity to immune killing. Ultimately, this study will help expand our understanding of immune evasion in bladder cancer, laying groundwork for better treatments.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572684
Name
Jones Natalie K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring Cytoprotective Mechanisms in the Immune Evasion of Bladder Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Bladder Cancer; Cell Death Resistance; Cytoprotection; Immune Evasion; Immuno-Oncology; Immunotherapy; Therapy Resistance; Urothelial Carcinoma
Abstract
Bladder cancer is the tenth most prevalent cancer worldwide, and the number of new cases per year is expected to double by 2040. Immunotherapy has emerged as an effective way to stimulate the immune system against cancer, and while this has improved clinical outcomes, most bladder cancer patients do not respond well. In order to work toward better treatments, we must understand how bladder cancer evades immune killing. Recent studies have shown that immune attacks on tumour cells are usually sublethal; to kill tumour cells, immune cells have to inflict more damage than their target can recover from, as cancer cells use cytoprotective pathways to mitigate damage. However, the clinical relevance of these pathways in immune evasion has not been explored. We propose that cytoprotective pathways in bladder cancer cells contribute to resistance to immune killing, and we aim to identify relevant mechanisms of immune evasion in human bladder tumours. To investigate this, human T cells will be co-cultured with bladder cancer cell lines, and tumour cell survival will be assessed through either live-cell imaging or flow cytometry. These results will indicate which cell lines are more resistant to immune killing, and RNA sequencing will be used to identify possible mechanisms of resistance. To confirm their clinical relevance, these results will be compared with pathways identified in data from human bladder cancer patients. Candidate pathways will then be blocked or stimulated in co-culture assays to validate whether changing their level of function impacts sensitivity to immune killing. Ultimately, this study will help expand our understanding of immune evasion in bladder cancer, laying groundwork for better treatments.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jones, Natalie K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~